ZORYVE (roflumilast) topical cream 0.15%
Once-daily & steroid-free, for patients down to 6 years old

PIVOTAL SAFETY

CONSISTENTLY WELL TOLERATED AND SAFE

Symptoms illustrated. Not an actual patient.

SAFE FOR ANY LOCATION

  • Low rates of stinging or burning (1.6%)4*
  • Not associated with folliculitis, atrophy, striae, or HPA-axis suppression1
  • Low rate of discontinuation due to adverse events (1.6% and 1.1% with ZORYVE and vehicle, respectively)1

*Low rates of hot tingling/stinging sensation reported in patient-rated tolerability assessments 10–15 minutes after first application: 1.6% with ZORYVE (n=883) vs 2.0% with vehicle (n=451).

Most common adverse reactions with ZORYVE: headache, nausea, application site pain, diarrhea, and vomiting.Adverse reactions reported in ≥1% of patients treated with ZORYVE for 4 weeksApplication Site PainZORYVE(n=885)(n=451)VEHICLEHeadache26 (2.9%)4 (0.9%)Nausea17 (1.9%)2 (0.4%)13 (1.5%)3 (0.7%)Diarrhea13 (1.5%)2 (0.4%)Vomiting13 (1.5%)2 (0.4%)
Most common adverse reactions with ZORYVE: headache, nausea, application site pain, diarrhea, and vomiting.(n=451)HeadacheNauseaApplication Site PainDiarrheaVomitingZORYVE(n=885)26 (2.9%)17 (1.9%)13 (1.5%)13 (1.5%)13 (1.5%)VEHICLE4 (0.9%)2 (0.4%)3 (0.7%)2 (0.4%)2 (0.4%)Adverse reactions reported in ≥1% of patients treated with ZORYVE for 4 weeks
SEE EFFICACY
DATA 

Actual clinical trial patient

LEARN ABOUT THE
FORMULATION 

Actor portrayal

REQUEST A
REPRESENTATIVE 

Actor portrayal